Spero Therapeutics (NASDAQ:SPRO) reported its Q3 earnings results on Monday, November 13, 2023 at 04:05 PM.
Here’s what investors need to know about the announcement.
Earnings
Spero Therapeutics missed estimated earnings by 100.0%, reporting an EPS of $-0.06 versus an estimate of $-0.03.
Revenue was up $23.47 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.11 which was followed by a 3.45% drop in the share price the next day.
Here’s a look at Spero Therapeutics’s past performance:
| Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.34 | -0.33 | 0.04 | -0.30 |
| EPS Actual | -0.23 | -0.25 | 0.55 | -0.33 |
| Revenue Estimate | 1.07M | 1.00M | 22.87M | 5.42M |
| Revenue Actual | 2.72M | 2.07M | 47.44M | 2.01M |
To track all earnings releases for Spero Therapeutics visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
